Y-mAbs Therapeutics Inc
YMAB
Company Profile
Business description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Contact
202 Carnegie Center
Suite 301
PrincetonNJ08540
USAT: +1 646 885-8505
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
107
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.70 | 2.30 | 0.03% |
| CAC 40 | 7,766.71 | 43.24 | 0.56% |
| DAX 40 | 24,206.91 | 133.24 | 0.55% |
| Dow JONES (US) | 44,249.65 | 156.71 | -0.35% |
| FTSE 100 | 8,854.18 | 47.65 | 0.54% |
| HKSE | 24,148.07 | 260.24 | 1.09% |
| NASDAQ | 20,399.54 | 12.98 | -0.06% |
| Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
| NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
| S&P 500 | 6,223.89 | 6.09 | -0.10% |
| S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
| SSE Composite Index | 3,497.48 | 24.35 | 0.70% |